A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Stifel analysts adjusted their stance on Exelixis (NASDAQ:EXEL) shares, raising the price target to $36 from the previous $30, while keeping a Hold rating on the stock. The new price target reflects ...